- Markets
- Healthcare
- EVERESTO
EVERESTO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Everest Organics Gets Korea Drug Master File Approval For Its Rabeprazole Sodium API
Feb 18 (Reuters) - Everest Organics Ltd EVER.BO:
GETS KOREA DRUG MASTER FILE APPROVAL FOR ITS RABEPRAZOLE SODIUM API
Source text: ID:nBSE6fkNMq
Further company coverage: EVER.BO
(([email protected];;))
Feb 18 (Reuters) - Everest Organics Ltd EVER.BO:
GETS KOREA DRUG MASTER FILE APPROVAL FOR ITS RABEPRAZOLE SODIUM API
Source text: ID:nBSE6fkNMq
Further company coverage: EVER.BO
(([email protected];;))
Everest Organics To Consider Fund Raising
Dec 9 (Reuters) - Everest Organics Ltd EVER.BO:
EVEREST ORGANICS LTD - TO CONSIDER FUND RAISING
Source text: ID:nBSE9zkwnv
Further company coverage: EVER.BO
(([email protected];))
Dec 9 (Reuters) - Everest Organics Ltd EVER.BO:
EVEREST ORGANICS LTD - TO CONSIDER FUND RAISING
Source text: ID:nBSE9zkwnv
Further company coverage: EVER.BO
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Everest Organics do?
Everest Organics Ltd was established in 1993 to manufacture bulk drugs such as Omeprazole and Ciprofloxacin. Production began in 1996 in Hyderabad.
Who are the competitors of Everest Organics?
Everest Organics major competitors are Bal Pharma, Tyche Inds, Smruthi Organics, Mangalam Drugs&Org., SMS Lifesciences, Nectar Lifesciences, Lasa Supergenerics. Market Cap of Everest Organics is ₹303 Crs. While the median market cap of its peers are ₹156 Crs.
Is Everest Organics financially stable compared to its competitors?
Everest Organics seems to be less financially stable compared to its competitors. Altman Z score of Everest Organics is 2.12 and is ranked 4 out of its 8 competitors.
Does Everest Organics pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Everest Organics latest dividend payout ratio is 34.97% and 3yr average dividend payout ratio is 34.97%
How has Everest Organics allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable
How strong is Everest Organics balance sheet?
Balance sheet of Everest Organics is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Everest Organics improving?
The profit is oscillating. The profit of Everest Organics is -₹4.15 Crs for TTM, ₹0.14 Crs for Mar 2024 and -₹0.18 Crs for Mar 2023.
Is the debt of Everest Organics increasing or decreasing?
The debt of Everest Organics is decreasing. Latest debt of Everest Organics is ₹50.61 Crs as of Sep-24. This is less than Mar-24 when it was ₹56.15 Crs.
Is Everest Organics stock expensive?
Everest Organics is not expensive. Latest PE of Everest Organics is 0.0, while 3 year average PE is 90.39. Also latest EV/EBITDA of Everest Organics is 52.42 while 3yr average is 78.4.
Has the share price of Everest Organics grown faster than its competition?
Everest Organics has given better returns compared to its competitors. Everest Organics has grown at ~15.92% over the last 7yrs while peers have grown at a median rate of 3.17%
Is the promoter bullish about Everest Organics?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Everest Organics is 61.09% and last quarter promoter holding is 74.15%
Are mutual funds buying/selling Everest Organics?
There is Insufficient data to gauge this.